



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,446	05/08/2006	Teruo Nishida	868-007	4642
25191	7590	04/15/2009		
BURR & BROWN				
PO BOX 7068				
SYRACUSE, NY 13261-7068				
EXAMINER				
UNDERDAHL, THANE E				
ART UNIT		PAPER NUMBER		
1651				
MAIL DATE		DELIVERY MODE		
04/15/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/540,446

Applicant(s)

NISHIDA ET AL.

Examiner

THANE UNDERDAHL

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 January 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 9-14 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 9-14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SG/US)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Detailed Action

This Office Action is in response to the Applicant's reply received 1/15/09. Claims 9-14 are pending. No claims are withdrawn. Claims 1-8 are cancelled. No claims have been amended. Claims 9-14 are new.

Response to Applicant's Arguments

In the response submitted by the Applicant the 35 U.S.C § 102 (b) rejection of claims 1-7 based on Aucoin et al. is withdrawn in light of Applicant's amendment.

Rejections Necessitated by Applicants Amendment

The following rejections are made in response to the Applicant's amendments to the claims.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 9-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Livant et al. (U.S. Patent # 6140068, 2000).

These claims are to a composition comprising:

- An ophthalmologically effective amount of the peptide PHSRN
- At least one member from the Markush group listed in Claim 1 such as an excipient, tonicity agent, buffer agent, base material and pH adjuster

The ophthalmologically effective amount of PHSRN is further defined in claims 10 and 11 as a concentration of 0.00001% to about 1% or more succinctly as 2 μM to about 2000 μM . The Tonicity agent is further limited to NaCl or KCl.

The limitation "an ophthalmological composition" is an intended use and does not impart a structural relationship, such as an additional component, to the composition (M.P.E.P. § 2111.02 II). Since compositions are defined and limited by their components, these limitations are not further limiting. Any composition that teaches the components and the concentrations limited in claims 10 and 11 will read on the claims since a composition of the same structure will presumably have the same properties or function (M.P.E.P. § 2112.01 I and II).

Livant et al. teach a composition comprising normal saline, which is a tonicity agent and excipient, with the peptide PHSRN (calculated MW = 609.64 g/mol) at a concentration of 660 μM (Example 11). Normal saline inherently contains the tonicity agent sodium chloride.

Therefore the references anticipate claims 9-12.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 9- 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Livant et al. as applied to claims 9-12 above and in further view of Alm et al. (U.S. Patent # 5733870) with support of Answers.com .

The descriptions of claims 9-12 are recited in the 35 U.S.C § 103 rejection above and are applied here as well. Claim 13 limits the composition to either sodium hydrogen phosphate or sodium dihydrogen phosphate as a buffering agent. Claim 14 limits the composition to comprising petrolatum or liquid paraffin. While Livant et al. teach saline in their composition they do not teach petrolatum or liquid paraffin. Regardless this would be obvious to one of ordinary skill in the art by the time the invention was made in view of the teachings of Alm et al.

Alm et al. teach that ointments containing liquid paraffin or phosphate buffered saline combined with fibronectin is useful for wound healing (Alm, col 1, lines 30-35 and Example 1, 3 and 4). Phosphate buffered saline inherently contains sodium hydrogen phosphate as supported by Answers.com (definition-phosphate buffered saline) However Livant et al. teaches that both fibronectin and PHSRN induce fibroblast invasion which is attributed to accelerate wound healing (Livant, see Example 7, Fig. 4 and Example 12, Fig. 9 and 10). Also Livant et al. teach that PHSRN is a peptide sequence derived from fibronectin. Therefore since Livant et al. teach that both fibronectin and PHSRN are effective at wound healing it would be obvious that one of ordinary skill in the art would recognize that both are art-recognized compounds for the same purpose and it would be obvious to substitute one for the other (M.P.E.P. §

2144.06 II) and obtain predictable results in wound healing (KSR International v. Teleflex Inc. 550 U.S. ___, 127 S. Ct. 1727, 82 U.S.P.Q.2d 1385 (2007)).

Therefore claims 9-14 are obvious in view of the above references.

No claims are currently allowed in this application.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

In response to this office action the applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP § 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 U.S.C. § 102 or 35 U.S.C. § 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is requested to provide a list of all copending U.S. applications that set forth similar subject matter to the present claims. A copy of such copending claims is requested in response to this Office action.

CONTACT INFORMATION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thane Underdahl whose telephone number is (571) 272-9042. The examiner can normally be reached Monday through Thursday, 8:00 to 17:00 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Thane Underdahl
Art Unit 1651

/Leon B Lankford/
Primary Examiner, Art Unit 1651